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There are approximately 600 E3 ligases in the human genome, and they can be sub-divided into RING type and HECT domain ligases. [1] Within the HECT E3s is as mall group (9 in total) referred to as the Nedd4s uperfamily,w hich includes the WWP1, WWP2, Nedd4, ITCH and Smurf2U bl igases. [2] The 3D crystal structuresh ave been resolved for the HECT domains within Nedd4, [3] WWP1, [4] and WWP2. [5, 6] Accumulating evidence suggests that the Nedd4 ligases, and notably WWP1 and WWP2, are frequently mis-expressed in cancer. [7] [8] [9] Theiro verexpression in animalm odels causesi ncreased tumour outgrowth, [10] and they also selectively control key oncogenic signaling events linked to both cancerinitiation and spread. [11] There have been an umber of recent attempts to develop HECT ligase inhibitors, and more specifically targeting the Nedd4s ub-family.H eclin wasi dentified from ab icyclic peptide librarys creen and can selectively inhibit Smurf2, Nedd4 and WWP1byi nducingaconformational change that causes oxidation of the actives ite cysteine. [12] Chlomipraminee mergeda sa candidate ITCH ligase inhibitor based on an enzymatic assaybasedh igh throughput screen and was shown to block both ITCH auto-ubiquitination and substrate-specific p73 ubiquitination, althoughI C50 values are in the low millimolarr ange. [13] Using ac ovalent tethering method, an ew class of Nedd4 ligase inhibitors were identified and shownt or eact with a non-catalytic cysteinet oh inderu biquitin binding to this exosite and subsequent enzymatic processivity. [14] Additional attempts to discover Nedd4 inhibitors have utilisedi ns ilico modelling approaches supported by thermal shift binding experiments and revealed that derivatives of indole-3-carbinol may also bind to the processivity exosite in the Nedd4 catalytic HECT domain and inhibit substrate-specific ubiquitination linkedt ooncogenic signalling events. [15, 16] Here, we focused our efforts on developing small molecule inhibitors of the WWP2 ubiquitin ligase, an enzymet hat can cause ubiquitin-dependent degradation of specific tumour suppressor proteins that are commonly lost in many types of cancer,n amely Smad transcriptionf actors, PTEN, and Oct4. To that aim, we have used high-throughput screening to identify hits from the NCI DiversityS et V and NCI Approved Oncology Set V smallm olecule libraries, we have confirmed binding to WWP2b yN MR spectroscopy,a nd used ac ombination of STD NMR,D iffErential EPitope mapping (DEEP)-STD NMR and docking calculations to generate for the first time an NMR-validated 3D molecular model of aW WP2-inhibitor complex. To discover first generation WWP2u biquitin ligase inhibitors we used a9 6-well plate format high-throughput screen (HTS) using recombinant proteinsa nd auto-ubiquitination as ar eadout for WWP2 activity (Figure 1a) .
Initially,t od evelopa nd optimise the HTS assay full-length WWP2( WWP2-FL) expressed as aG ST fusionp rotein in bacteria was attached onto glutathione-coated plates and then incubatedw ith recombinantE 1, E2 enzymes and Flag-tagged ubiquitin (Supporting InformationF igure S1a). The specificity for WWP2a uto-ubiquitinationw as confirmed by detection of UbFlag conjugated WWP2 in the presence of all assay componentsa nd confirmed using acatalytically inactive WWP2-FL C838A mutant (Supporting Information FigureS1b) . Next,w eu sed this assay to screen the NCI Diversity Set V and NCI Approved Oncology Set V small molecule libraries consisting of 1,593 and 450 compounds, respectively.T he initial screens were run as single shot assays at ac oncentration of 10 mm and 0.1% DMSO,w ithZ ' values over 0.5 suggestingt hat these plate assays were robust. The controls fore ach library screen showedn os ignificant difference betweent he buffer and E3 only controlsa nd no significant effect was observed in the presence of DMSO (Supporting Information Figure S1c ). Results were normalised using the high and low controlst oc alculate the percentage residual activity compared to the DMSO control. At hreshold of 70 %( > 2SDf rom the DMSO control mean) was used to determine which compounds would be selected for further testing. Wei dentified 24 initial hits from the NCI Diversity Set Vs creen, but no hits emerged from the NCI Oncology set ( Figure 1a and Supporting Information Figure S1d ). Potential hits emerging from the single shot assays were then tested in triplicate under the same assayc onditions and at 10 mm compound concentration, and 17 of the initial 24 hits demonstrated significant decrease in WWP2 activity (Figure 1b ). These were then further ranked more stringently based on < 20 %r esidual activity thresholds, and furtherd e-selected based on dose-dependent WWP2 inhibition (Supporting Information Figure S2 ). In total, 10 potentialh it inhibitors with varied structural compositions were identified andt he majority of these gave IC50 values in the low micromolar range (Supporting Information Ta ble S1), and five of these inhibitors had IC50 values below 3 mm (Table 1) .
We next further analysed all 10 selected hit compounds based on counter assays against E1, E2, Nedd4 and WWP1 ubiquitin ligases. Since the WWP2 auto-ubiquitination is dependento np rior sequential activation of ubiquitin by E1 and E2 ubiquitin ligases, we addressed whethera ny of the lead inhibitors were affecting this ubiquitin priming step earlier within in the auto-ubiquitination cascade. We therefore developed and optimised ubiquitination assays to measureU bcH7 (E2) and Uba1 (E1) activities. For UbcH7, we used as imilar plate assay approacha su sed to measureE 3a ctivity but used bacterially His-tagged UbcH7 and bound this protein onto nickel-coated 96-well plates. Once the assay was optimised to obtain significant 100 %a nd 0% activity controls, compounds were tested at the same initial concentrations as used in the GST-WWP2-FL screening, and no significant decrease in activity was observed for all compounds in the His-E2 ubiquitination assay (Supporting Information Figure S3a ). To assessc ompound effects on E1 activity,w eu sed ad ifferent gel-based approach duet od ifficulties in developing robusta nd reproducible plate assays. RecombinantH is-Uba1 and ubiquitin undergo E1-mediated transthiolation when incubated together andt he formation of higherm olecular weight mono-Ub-E1 conjugates was clearly apparent when separated by SDS-PAGE and stained with Coomassie Blue. In the presence of the WWP2 lead inhibitory compounds we found no discernible impact on E1 ubiquitin conjugation (Supporting Information Figure S3b ). Hitc ompounds were next tested against Nedd4 and WWP1 to find out whether they were capable of inhibiting otherH ECT E3 ligases in the same family as WWP2. GST-tagged Nedd4a nd Histagged WWP1 were immobilisedo nto glutathione coated and nickel coated plates, respectively.A uto-ubiquitination levels were determined using HRP-conjugated anti-Flaga ntibody and TMB substrate. Both Nedd4a nd WWP1 produced as ignificant increasei nO Dw hen in the presence of E1, E2, and ubiquitin, unlike all other reactions (Supporting Information Figure S3c ).
There wasn os ignificant differenceb etween reactions which lacked one or more components, showingt hat Nedd4 and WWP1 are capable of auto-ubiquitination under these assay conditions. All inhibitors tested demonstrated some degree of Figure S3d ). We next tested for substrate-specific effects, and determined whether these inhibitors could affect WWP2-dependentP TEN ubiquitination. Reactionsc ontained E1, E2, WWP2, PTEN, ubiquitin andA TP and were analysed by western blotting. In the presence of selected hit compounds representing ab road range of IC50 values based on the HTS assay,i ti s clear that each can robustly inhibit WWP2-dependent PTEN ubiquitination ( Figure 2 ).
Ligand-based NMR wast hen used to confirm binding of hit compounds to the WWP2 HECT catalytic domain. We used i), Saturation Transfer Difference (STD) NMR and ii), Carr-PurcellMeiboom-Gill (CPMG) NMR experiments, two widely used techniques for lead screening in drug discovery. [17] STD NMR spectroscopy relies on protein-selective saturation being transferred only to the bound ligands in fast exchange with the receptor. [18, 19] Hence, the presence of signals in the STD difference spectra of as ample containing one ligand (or more) in the presence of ar eceptor indicates binding. CPMG NMRe xperiments, also called T 2 -filter experiments, rely on af ilter (repeating spin-echo buildingb locks in the pulse sequence) whose aim is to eliminate the signals comingf rom large molecules (usually having as hort transverse relaxation time, T 2 ). [20] Bound ligands transiently acquireaT 2 similart ot hat of the receptor,a nd so their signal will be filtered out as well. In the CPMG spectrum, the absence (or strongr eduction) of ligand signals in the presence of areceptor indicates binding.
The NMR screening provided clear-cutr esults for six of the hit compounds,a ss hown by positive binding resultsi nb oth the STD and CPMG NMR experiments (1, 2, 16, 17, 18 and 20, see Ta ble 1, Supporting Information Table S1 and Figure S4 ). Compounds 12, 19 and 21 were excludeda sthey showed very weak signals both in the binding experimentsa nd in the control spectra, probablya scribable to solubility issues;w hile compound 7 showedn oS TD signals. It is important to highlight that fast exchange between the free and the bound state is an essential condition for STD NMR. [21] The STD signal is detected in the ligand free state;i ft he ligand resides within the binding pocket for al ong period of time, the saturation is not sufficiently accumulatedd uring the saturation time. The low IC50 value determined for compound 7 (0.84 mm)a nd the absence of STD signals for this hit could indicate too strong an affinity of binding. This would make compound 7 unsuitable for ligand-based NMR observation, but the resultsd on ot necessarily exclude it as abinder.
STD NMR has also great potential in structurally elucidating the binding mode of al igand in complex with the protein at atomicd etail,p roviding the binding epitope mapping of the ligand. [21] Among the six identified binders based on STD-NMR data, we selected NSC288387 (compound 20)s ince it showed the clearest STD signals (probably as ac onsequence of its midrange IC50, of 2.30 mm)t od eepen the structurala nalysisb y performing STD binding epitope mapping. The STD binding epitope mapping ( Figure 3a) s uggestst hat the main recognition element in the complexb etween WWP2 HECT and compound 20 is the unsubstituted N-phenyl ring (labelled Bi n Figure3); ring Aa nd the aliphatic ether adjacent to it show weaker interactions, suggesting that this part of the molecule would be the most solvent exposed.
We then used computational techniques to identify the binding site on the WWP2 HECT domain (based on the PDB ID:4 Y07 validation of the 3D model of the complex,w ee mployedt he newly developed DEEP-STD NMR approach (relying on protein irradiation at differential frequencies) which allows the identification of the types of amino-acids lining the binding pocket that make inter-molecular contactsw ith specific single protons of the ligand. [22] The DEEP-STD NMR data obtained by differential irradiation of the protein at 0.50 and 1.50 ppm (Figure 3c ) provideda dditional experimentals upport for the 3D molecular model of the complex generatedb yt he docking approach. Frequencies 0.50 and 1.50 ppm correspond to methyl groups of valine and isoleucine, and the arginine b/g protons, respectively (see SupportingI nformation Table S3 and S4). Closer inspection of the docking solution in the putative binding pocket reveals the presence of Val806 and Arg803 at close distances from ring Ao ft he ligand (Figure 3d and Supporting InformationT able S5).
Remarkably,t he docking solution structure shows ligand protons c, da nd ep ointing towards the methyl group of Val806, and protonsfand g, pointing towards the Arg803, on the opposite side of the bindingp ocket. This is in perfect agreement with the DEEP-STDf actors (1.5/0.5 ppm) observed for these protons (Figure 3c ): protons c, dand eshow negative DEEP-STD factors, andp rotons fa nd gs how positive DEEP-STD factors (suggestingv icinity with protein residues resonating at 0.5 and 1.5 ppm, respectively). The excellent match between the docking solution of compound 20 in the putative binding pocket and the pharmacophore of both the ligand and the binding site (obtained by STD NMR and DEEP-STD NMR, respectively) give us solidg round to propose the model as the first 3D structure of aW WP2 inhibitor bound to its target (Figure 3a nd Supporting Information Figure S5 ). Furthermore, this NMR-validated model is supported by molecular dynamics simulation studies demonstrating stability of the complex (Supporting Information Figures S6-S8) .
In summary,t he compounds discovered in this study represent the first generation of WWP2 ubiquitin ligase inhibitors. Additionally,t hrough ac ombination of HTS, ligand-based NMR, DEEP-STD NMR and dockingc alculations we have been ablet o propose for the first time a3 Dm olecular modelo faW WP2-inhibitor complex. Collectively,t hese data provide af ramework for developing new classes of ubiquitin ligase inhibitors that can progress through further organic synthesis to improve compound activity and specificitya nd have potential tog enerate lead therapeutic compounds. We are currently workingt owards unravelling the mechanism of inhibition by thesen ovel ligandsa nd further probingt he ligand binding sites using combined DEEP-STD NMR and crystallographya pproaches. We anticipate that, buildingu pf rom this work, subsequent lead optimization will provide novel analogues that can progress through to potentialtherapeutic compounds.
